摘要
目的:检测TopoⅡ、p53、Ki-67、c-erbB-2在乳腺癌组织中的表达,分析其与乳腺癌临床病理特征间的关系。方法:采用免疫组化方法检测66例未经抗肿瘤治疗的原发性乳腺癌组织中Topo II、p53、Ki-67、c-erbB-2的表达情况。结果:乳腺癌组织中TopoⅡ、p53、Ki-67、c-erbB-2阳性表达率分别为57.6%(38/66)、60.6%(40/66)、62.1%(41/66)、51.5%(34/66),Topo Ⅱ、Ki-67、p53、c-erbB-2表达与患者年龄、肿瘤大小无关(P>0.05),TopoⅡ、p53、Ki-67、c-erbB-2与淋巴结转移相关(P<0.05),其中p53、Ki-67、c-erbB-2与肿瘤临床分期相关(P<0.05)。结论:联合检测乳腺癌组织中c-erbB-2、p53、Ki-67可以作为判断乳腺癌患者预后的有效指标,TopoⅡ在乳腺癌中的表达可作为指导乳腺癌化疗的重要指标。
Objective：To evaluate the clinicopathological significance of expressions of Topo Ⅱ,p53,Ki-67,c-erbB-2 in breast cancer,and analyze the relationship with clinicopathologic characteristics of breast carcinoma.Methods： Sixty six cases of paraffin-embedded specimens of breast carcinoma were studied by immunohistochemica1 technique.Results： The positive rates of TopoⅡ,p53,Ki-67,c-erbB-2 were 57.6%（38/66）,60.6%（40/66）,62.1%（41/66）,51.5%（34/66） respectively.The expressions of TopoⅡ,p53,Ki-67,c-erbB-2 were not related with age,tumor size,breast cancer tissues（P0.05）,but with node metastases and clinical stage.Conclusion： The results suggested that TopoⅡ,c-erbB-2,p53,Ki-67 can be effective markers for estimating the prognosis of breast cancer.TopoⅡ expression of breast carcinoma can be important digital index of instructing chemotherapy and determining prognosis.
出处
《现代肿瘤医学》
CAS
2011年第8期1545-1547,共3页
Journal of Modern Oncology
